Gyre Therapeutics, Inc.
GYRE
$8.68
-$2.53-22.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -64.18% | 99.90% | -71.73% | 90.39% | 235.65% |
| Total Depreciation and Amortization | 28.92% | 52.92% | 124.75% | -25.16% | 45.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.23% | -99.27% | -54.15% | -39.06% | 2.53% |
| Change in Net Operating Assets | 20.14% | -135.56% | -173.71% | -1,667.43% | -218.32% |
| Cash from Operations | -104.47% | -182.08% | -77.24% | -221.18% | -72.31% |
| Capital Expenditure | 47.19% | 102.80% | 64.89% | 41.22% | 86.74% |
| Sale of Property, Plant, and Equipment | -98.00% | -17.37% | -101.38% | 62.69% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 129.66% | -57.53% | 55.42% | -23.25% | -19.18% |
| Cash from Investing | 127.24% | -249.66% | 55.80% | -2.76% | 5.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 122.64% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 104.26% | -61.44% | -- | -- | -- |
| Foreign Exchange rate Adjustments | 208.70% | -210.39% | -38.01% | 91.33% | -123.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 186.79% | -154.55% | -109.82% | -209.82% | -225.43% |